INGREDIENTS: Huge heart, open mind, embraces others, grit, determination, big brother, future fireman or engineer, lollipop lover, allergic to milk, tree nuts and seeds

CONTAINS: COURAGE®
MISSION:
FARE (Food Allergy Research & Education) is the world’s leading food allergy advocacy organization and the largest private funder of food allergy research. Our mission is to improve the quality of life and the health of the approximately 32 million people in the United States living with food allergies, and to provide them hope through the promise of new treatments.

VISION:
FARE is transforming the future of food allergy through innovative initiatives that will lead to increased awareness, new and improved treatments and prevention strategies, effective policies and legislation, and novel approaches to managing the disease.
Dear Friends of FARE,

The year 2019 was transformative and groundbreaking for FARE. I am pleased to present the 2019 Impact Report. Since its launch one year ago, our Contains: Courage® Campaign has received commitments of $67.8 million toward FARE’s $200 million goal, which will directly support trailblazing advances in food allergy research, education, advocacy and awareness.

We have made real gains in research and patient care, from discoveries made with FARE support, to FARE Patient Registry® enrollment of nearly 10,000 patients. We are enhancing connections between the Registry and the FARE Clinical Network and restructuring the Network to engage the strengths of each participating Center of Excellence while providing data coordination and biobanking of patient specimens. In November, FARE convened an Oral Immunotherapy (OIT) in Practice Summit, seeking a consensus path forward to help patients access and evaluate this therapeutic option.

Education, advocacy and awareness efforts have also shone this year. The Food Allergy Safety, Treatment, Education and Research Act (FASTER Act, H.R. 2117) to label sesame, update allergen labeling laws, enable data collection and support research has gathered 37 congressional co-sponsors to date. Our 2019 Contains: Courage® FARE Summit drew a historic crowd of more than 1,000. The Teal Pumpkin Project® and our push for safe airline policies helped FARE earn one billion media impressions for 2019.

Food allergy is at a critical inflection point. Breakthrough treatment options are on the horizon, and a growing abundance of agricultural and consumer packaged goods for the 32 million Americans with food allergy are entering the market. FARE is proud of the accomplishments we report here and the momentum we have built toward achieving our mission, to improve the quality of life and the health of individuals with food allergies, and to provide them hope through the promise of new treatments.

Warmly,

Lisa Gable
Chief Executive Officer

Lisa Gable
Chief Executive Officer
FARE IS THE LARGEST PRIVATE FUNDER OF FOOD ALLERGY RESEARCH IN THE WORLD.

32 MILLION
Americans have food allergies
INNOVATION & TRANSFORMATION
FARE is raising $200 million to achieve the critical mass of research and investment needed to create measurable, enduring impacts for food allergy patients and their families. By accelerating our investments and support, we will create scale for advances and innovations that can mitigate risk, halt the rise of the disease, and disseminate the knowledge derived from our investments to health care providers and other professionals working with patients. Today’s emerging science offers new hope to those living with food allergies to create a better quality of life.

RESEARCH
FARE is the largest private funder of food allergy research in the world and a critical force within a comprehensive landscape of health and wellness partners. FARE’s commitment to help make life safer for those with food allergies has been recognized by grassroots advocates, donors and the scientific and medical communities. FARE is a catalyst for driving research and promotes collaboration through fundraising, communications, advocacy and data collection to ensure the voice of the patient is heard. In 2019, we have done this through the following initiatives:

RESEARCH INVESTMENT: To date, FARE has invested more than $100 million in food allergy research. Through our commitment to advocacy, we have helped to double food allergy research funding by the National Institutes of Health in the years since the Food Allergy and Anaphylaxis Network and the Food Allergy Initiative merged to form FARE. In 2019, FARE’s research investments have resulted in historic breakthroughs and advancements that will have long-lasting impact for the food allergy community.

• In a FARE-funded study published in the prestigious journal Science, Dr. Stephanie Eisenbarth (Yale
University), who received a 2017 Mid-Career FARE Investigator in Food Allergy Award, led a research team that discovered in mice a type of immune cell that drives IgE antibody production and anaphylaxis. The same immune cell type was also found in blood samples from human allergy patients.

• A study funded in part by FARE and published in the Journal of Allergy and Clinical Immunology by researchers at the University of North Carolina reported exciting safety and effectiveness data for extended peanut sublingual immunotherapy (SLIT) in children aged 1 to 11.

• The Food and Drug Administration Advisory Committee voted to recommend the approval of Aimmune Therapeutics’ groundbreaking peanut allergy treatment, AR101, for patients aged 4 to 17. FARE’s early investment and support for the research and development that may soon make AR101 widely available to patients is a critical component of our mission to which we are deeply committed.

**EVOLUTION OF THE FARE CLINICAL NETWORK:** Established in 2015 and now boasting 33 Centers of Excellence, the FARE Clinical Network is a collaboration among leading research and clinical institutions to better serve the 32 million Americans living with food allergies by driving the development of new food allergy therapies and improving the quality and accessibility of patient care. This year marked our first steps in the FARE Clinical Network’s evolution toward a next-generation patient care and research model. Our new structure will bring top institutions together to ensure that patients with food allergies have access to state-of-the-art diagnosis and treatment, short-term and long-term care, and research that addresses factors from discovery to application along the entire clinical and translational spectrum.
Our new FARE Clinical Network structure includes three levels that tap into the strengths of each participating institution:

- **Discovery Centers of Distinction** conducting novel research on treatments, diagnostics, prevention and improvements to care

- **Clinical Centers of Distinction** generating a gold-standard clinical trial network to accelerate development

- **Clinical Care Centers of Distinction** focused on exceptional patient care and community education

FARE has issued applications for membership in the redesigned FARE Clinical Network, which will launch in 2020.

**FARE PATIENT REGISTRY®:** The FARE Patient Registry® empowers individuals with food allergies or their legal representatives to help drive food allergy research forward by sharing their de-identified (anonymous) medical histories with the research community. This year Registry enrollment grew by more than 50 percent through November 2019, and the Registry is projected to surpass our target of 10,000 participants before year’s end, making it the world’s largest registry of food allergy patients. Through three simple online surveys, Registry contributors have provided vital data on food allergy demographics, reactions, treatments, outcomes, and mental health needs and services. The Registry also offers a clinical trial finder and a research portal with 40 users across institutions in the FARE Clinical Network, participating researchers and sponsors.

**COMMUNICATION AND COORDINATION CENTER:** To better harness FARE Clinical Network (FCN) and FARE Patient Registry® data, FARE is building additional resources to pool and leverage electronic medical records and patient specimens, accelerating the search for new tools and treatments. FARE is currently accepting applications to manage the FCN
Communication and Coordination Center, as well as the Biobank and Biomarker Discovery Center.

**FARE 2019 ORAL IMMUNOTHERAPY SUMMIT:** FARE is taking the lead in educating both physicians and patients about the safety and effectiveness of oral immunotherapy (OIT) as a treatment option for some food allergy patients. On November 6, 2019, FARE convened the first groundbreaking gathering of food allergy stakeholders in Houston in its inaugural OIT Summit. The Summit brought together leaders from National Institutes of Health, American Academy of Allergy, Asthma, and Immunology, American College of Allergy, Asthma and Immunology, Food and Drug Administration, FARE Clinical Network, community physician networks and patient advocacy organizations, reaching consensus on key information gaps and laying the foundation for better OIT education and access nationally. The presentations and dialog highlighted the need for accessible, evidence-based OIT regimens and education, and emphasized the importance of developing effective communication tools to help individuals affected by food allergy work with their physicians to make informed, shared decisions about whether to pursue OIT treatment.

**RESEARCH RETREAT:** In 2019, FARE convened more than 120 clinicians, industry representatives, scientists in academia and public service, and directors from the 33 Centers of Excellence in the FARE Clinical Network. Together, they shared experimental findings and explored opportunities to improve the quality of life and health for patients with food allergy and provide hope through the promise of new treatments. Presentations by the three 2015 recipients of Mid-Career FARE Investigator in Food Allergy awards reflected the power of FARE funding to move food allergy science forward.
INTERNATIONAL FOOD ALLERGY & ANAPHYLAXIS ALLIANCE (IFAAA):
Formed in 1999, IFAAA is a coalition of patient advocacy groups working to advance the interests of the food allergy community worldwide. The IFAAA’s first Partners in Action Day in 2017 brought together patient representatives to share their insights with regulators, drug and food manufacturers, scientists, clinicians and others. This year in Florence, Italy, Partners in Action Day drew 75 participants from 14 countries on five continents, bringing diverse patient perspectives to inform the direction of food allergy research and public policy.

FARE INVESTMENT IN RESEARCH: FARE has invested in building a research operation that offers leadership across food allergy, immunology, asthma and other atopic disease, and experience from leading academic institutions, medical non-profits, biopharma companies, life science consultancies and private-equity firms. This new team will drive FARE’s research capabilities to pioneering new heights.
FARE is taking a monumental step in advocacy efforts to influence the environment with opinion leaders and decision makers to create a better quality of life for those living with food allergies.

**THE FASTER ACT:** The 2019 introduction of H.R. 2117, the Food Allergy Safety, Treatment, Education, and Research Act (FASTER Act) was the culmination of more than a year of legislator education, policy refinement and advocacy by FARE, made possible through the championing of Congresswoman Doris Matsui of the Sixth District of California. The resulting legislation will improve the lives of the millions of Americans with food allergies by funding data collection on food allergy prevalence by the Centers for Disease Control, adding sesame to the list of covered allergens in the Food Allergy Labeling and Consumer Protection Act and creating flexibility to add emerging allergens in the future. This crucial legislation will also direct the National Institutes of Health to study the economic costs of living with food allergies and...
add food allergies to the Food and Drug Administration’s priorities for collecting patient experience data to support drug development. Since April, the bill has garnered 37 congressional co-sponsors.

**AIRLINES:** FARE continued to promote safety and accessibility in airline travel for those in the food allergy community. In a two-pronged public affairs effort, FARE CEO Lisa Gable reached out to the CEOs of America’s airline carriers to outline the burdens faced during travel by those with food allergies and ask for their voluntary commitment to stock epinephrine auto-injectors in all onboard medical kits. FARE also engaged with manufacturers of epinephrine auto-injectors to encourage their cooperation in supporting this change and will continue to work with trade groups such as Airlines for America to bring safety to those in flight. In addition, FARE is working with local and national media outlets, in an integrated approach with advocacy, to raise the awareness of this important issue.

**STANDARDIZING LABELING:** FARE and the Consumer Brands Association (formerly known as Grocery Manufacturers Association) announced a partnership between the two organizations through which they will work to address the need for federal, uniform standards for allergen labeling on consumer packaged goods. By working collaboratively on this joint effort, FARE seeks to improve allergen labeling guidelines to ensure there is clarity and consistency at the federal level.

**ELIJAH’S LAW:** On September 13, 2019, Elijah’s Law was signed by Governor Andrew Cuomo of New York. The first of its kind enacted in the United States, the law will require all childhood daycare programs to implement guidelines to prevent, recognize and respond to anaphylactic reactions. FARE worked closely with Thomas and Dina Silvera, who through the Elijah-Alavi Foundation ushered this bill through the legislature.
EDUCATION

FARE’s educational materials provide resources and strategies for managing food allergies across the lifespan, from school and camp to college and the workplace. Additionally, by partnering with learning institutions, allied health professionals and food service companies, FARE continues to improve the life and health for individuals with food allergies.

• Through our Community Outreach Award program, more than 230,000 individuals were reached via volunteer-led education, training and awareness initiatives.

• On average, more than 800 individuals register for each of FARE’s free online educational webinars, and thousands have participated in 2019.

• The FARE Support Group Stipend Program provided financial assistance to 27 support groups nationwide.

• FARE identified a need to provide straightforward, evidenced-based educational training on anaphylaxis. In 2019, 35,000 individuals have taken our free online course, Save a Life: Recognizing and Responding to Anaphylaxis.

COLLABORATOR PROGRAM: Launched in 2019, the Collaborator Program is a framework through which FARE can distribute food allergy resources and shareable content to organizations that care about food allergies or that want to learn more about the issue and share that knowledge with their audiences. Through the Collaborator Program, FARE has joined forces with 167 organizations with the potential to reach nearly 52 million people to spread food allergy awareness.

FARECHECK CERTIFIED®: For millions of Americans, dining away from home creates anxiety, stress and challenges, since one bite of a food allergen can have potentially
life-threatening consequences. FARE has developed the FARECheck Certified® training program to foster knowledge and awareness of food allergies and anaphylaxis among hundreds of thousands of food service workers across the country who can play vital roles in protecting the food allergy community. Targeted specifically to food service companies with in-house training capabilities, this certification program is designed to ensure that their training provides evidence-based information on food allergies and best practices for allergy-aware management. More than 6,500 individuals have received FARECheck Certified® training.

FARE COLLEGE FOOD ALLERGY PROGRAM: FARE launched the College Food Allergy Program in January 2014 with the goal of developing a comprehensive program to improve the safety and quality of life for college students with food allergies. This program offers resources for students and parents, as well as colleges and universities. Since the launch of its college program, FARE has made an impact on hundreds of colleges and universities around the country.

- Nearly 500 colleges received FARE food service training in 2019.
- 500 dining services administrators received FARE education and resources.
- Over 1,600 individuals attended college readiness webinar trainings.
TOGETHER OUR IMPACT IS ADVANCING CHANGE AROUND THE WORLD

$67.8 MILLION
has been committed toward our $200 million goal since December 2018

Nearly
10,000 PEOPLE
enrolled in the FARE Patient Registry®

1,000+ PARTICIPANTS
in the Contains: Courage® FARE Summit

37 CO-SPONSORS
confirmed for H.R. 2117, the FASTER Act

33 CENTERS OF EXCELLENCE
across the country in FARE Clinical Network

Potential reach of over
52 MILLION PEOPLE & 167 PARTNER ORGANIZATIONS
through our FARE Collaborator Program

1 BILLION MEDIA IMPRESSIONS
for FARE in 2019
CONTAINS: COURAGE® FARE SUMMIT

The inaugural Contains: Courage® FARE Summit was monumental for the education of food allergy families as FARE hosted more than 1,000 participants. Held in early November at the Gaylord National Resort & Convention Center near Washington, D.C., this dynamic gathering drew teens and adults living with food allergy along with family members, health professionals and other allergy stakeholders in the nation’s largest-ever educational food allergy event for families. With more than 60 sessions and 70 speakers, this signature event is unlike any other in the country.

“I Honestly loved every minute of it. The unbelievable support and conversation with people who truly ‘get it’ are priceless. The speakers were excellent and the information I came home with is very helpful.”

—a Summit attendee
TEAL PUMPKIN PROJECT®

Media coverage carried Teal Pumpkin Project® 2019 to countless households, broadcasting nearly 331 million media impressions for the campaign. The Teal Pumpkin Project® was featured in more than 3,300 stories this Halloween season and even appeared in a network television series.

Nearly 25,000 households pinned their addresses to the Teal Pumpkin Project® map in 2019. Participating U.S. households could be found in all 50 states, Washington, D.C., Puerto Rico, the Virgin Islands, and the Northern Pacific. Teal pumpkins were on display worldwide, welcoming food-allergic children to homes in 23 nations and territories on six continents and brightening more than 2,300 porches in Canada alone.

Every continent that is home to children participated in the 2019 Teal Pumpkin Project®
Imagine a world where every person feels liberated, courageous and empowered.

The Contains: Courage® Campaign is a transformative five-year fundraising and awareness campaign supporting families living with food allergies and educating ALL communities about the disease. In just one year, the Campaign has $67.8M of the $200M five-year goal committed and has engaged food allergy families across initiatives throughout 2019:

- FARE received hundreds of submissions from the food allergy community to be the faces of the campaign and help amplify the voices of those living with food allergies.

- Inclusive, food allergy-friendly Contains: Courage® sporting events gave food allergy families the opportunity to experience stadiums with confidence.

- The Contains: Courage® Corporate Think Tank in May 2019 assembled thought leaders across industries to learn, share, connect and take action to further FARE’s mission together.

- The first Contains: Courage® FARE Summit was held in November and engaged over 1,000 participants.

Our goal is to reach 330 million Americans with the Contains: Courage® Campaign to cultivate understanding of the disease’s complexity and clarify the role each American can play in ensuring that people with food allergies are safe and included. With your support, we will drive awareness locally and nationally, and raise a historic amount of funding for research to find new treatments, diagnostics and strategies for prevention.

Join forces with us to advance our critical work for families across America.
INGREDIENTS: Diver, traveler, hard worker, photographer, beach lover, gymnastics fan, future journalist, allergic to dairy, eggs, nuts and shellfish

CONTAINS: COURAGE®
Every dollar raised brings us closer to improving the quality of LIFE and the HEALTH of individuals with food allergies, and providing them HOPE through the promise of new treatments.
OUR DONORS (2019)

When you support FARE, you are joining the food allergy community that is coming together to make a change and bring hope to families living with this disease. We strive to be good stewards of our funds and to faithfully represent the voice of our community. We are grateful for the enduring commitment and support of our donors. Together, we will continue to drive breakthrough research, educate the community and advocate on behalf of all living with food allergies.

$5M+
Sunshine Charitable Foundation – Denise & David Bunning

$2.5M-$4.9M
Anonymous
Hartman Family Foundation
Cari and Michael J. Sacks

$1M-$2.4M
Anna-Maria and Stephen Kellen Foundation
Helen and David Jaffe, and the Jaffe Family
Staci and Adam Miller
Christine Olsen, MD, and Robert Small
Ira and Diana Riklis Family

$500,000-$999,999
DBV Technologies, Inc.
Genentech, Inc.
Naddisy Foundation, Inc.
OWYN

$250,000-$499,999
The Donald Levin Family Foundation
Mary and Marc Weiser

$100,000-$249,999
Anonymous
Anonymous
Dr. Louise Matthews and Mr. Thomas Flickinger (Edward E. and Marie L. Matthews Foundation)
Trachte Family Foundation

$50,000-$99,999
Aimmune Therapeutics
Andrew and Dana Stone Family Foundation

Baron Capital Management, Inc.
Hillary and Benjamin Carter
Ceres Foundation, Inc.
John and Judith Hannan
Harris Family Foundation
Hittman Family Foundation
Indian Trail Charitable Foundation, Inc.
Mandelbaum Family
Sanofi
YumEarth

$10,000-$49,999
Maria Acebal
Pamela Ader
Bruce Alexander
Allan S. Gordon Foundation
David and Dr. Sharman Altshuler
Amir and Rosita Manocherian Family Foundation
Janet Atwater
Amy and Keith Barnett
Blavatnik Family Foundation
Stephen and Camilla Brauer
Alisa Brodkowitz
Children’s Hospital of Philadelphia Allergy
Compass Group
Daedalus Foundation, Inc.
David & Sondra Mack Foundation, Inc.
Enfamil
Enjoy Life Natural Brands, LLC
Wende Fox Lawson
Free2B Foods
Lisa and James Gable
Gayden Family Foundation
Daniel and Laura Gold
Robert and Abby Goldstein
Antoinette and Michael Griffith
Hackberry Endowment Partners
Harbor Seafood, Inc.
Irving T. Bush Foundation
Christine Johnson
Kaleo, Inc.
The Karin and Dean Teglia Family Foundation
Michael and Beth Klein
Paul and Julie Leff
LGA Family Foundation
Lucile Packard Foundation for Children's Health
Scott Malkin
McNamara Purcell Foundation
Merkel Foundation
National Peanut Board
Rebecca and Rob Nichols
The Palin Family Foundation
Peter R. Schneider Private Family Foundation
Pfizer, Inc.
Phoenix Suns Charities
Pittsburgh Foundation
Proskauer Rose LLP
Elise Purcell and Mark Flippo
Jonathan and Joelle Resnick
Rob Rich
Richard & Bette Saltzman Foundation
Robert J. Kahn Foundation
Bobbi Shah
Carole Steele
Stern Family Philanthropic Foundation
Laura Tisch Broumand
UCLA Health
Morris and Gail Yamner
Jaimie Yeh

$5,000-$9,999
Abramson Family Foundation
Lisa Abramson
Barry Aldeman
AmazonSmile Foundation
American College of Allergy, Asthma and Immunology
Robin and Philippe Amouyal
Jenny Andjelkovic
Andrea Singer Pollack Rev Trust
Ann & Robert H. Lurie Children’s Hospital of Chicago
Joan Ast
Joseph Auth
Robert Belfer
C.A. Shea & Company, Inc.
Campbell Family Foundation
Phillip Canfield
Capital Group Co. Charitable Foundation
Carl C. Icahn Foundation
Chicago Wolves Charities
Children's Hospital Los Angeles
Nancy Wikle
Mike and Rita Wilson
Lisa Zagorin

$2,500-$4,999
Dawn Alling
American Junior Golf Foundation ACE Grant
Andrew & Ann Tisch Foundation, Inc.
Sarah Andrysiak
Apple, Inc.
Carl and Eva Aschenbrener
Dennis Askwith
Bluhm Family Charitable Foundation
Vanita Boswell
David Boule
Butlein Family Foundation
James Caissy
Mariah Collins
Kathleen Crockett
David Drewes
Shon Dwyer
Robert Fair
Diane Felenstein
Fifth Generation, Inc.
Foublie
Julie Friedland
Josh and Tara Geise
George & Judith Arangio Foundation Trust
Gluten Free Gloriously

Google, Inc.
Batsheva Halpern
Hamilton Execucions
Herbert O. Wolfe Foundation
Elizabeth Holloway
Cathy Jefferson
Jerome J. and Ursula Choromanski Family Foundation
Ronald Kahn
Amy and Marty Kaplan
Julie Karish
Neil Katz
Evelyn Kenvin
Jackie Leopold
Lonnie & Jay Lischka Family Foundation
David Ludwig
Magic Power Co. Ltd.
Lucy Mangum
Deirdre McDonald
McMahon Associates, Inc.
Joseph Mele
Amy Mijas
Diana and Jay Moss
Richard Munaretto
Natter Family Foundation
Debbie Nazarian
Neuberger Berman
Open Society Institute
Sudhir and Hema Patel

Kraig Peterson
Pixie Lizzie
Michael Rauber
Aislinn Rennison
Daniel Rood
Rosetta W. Harris Charitable Lead Trust
Jacob Schowalter
Skelmir, LLC
Brandy Solinsky
Soros Fund Charitable Foundation
Kathy Stapleton
Stephen Colbert Americone Dream Fund
Virginia Stoddard
Tip Top Poultry, Inc.
Tri-State Food Allergy and Anaphylaxis Support Group
Ciara Trickett
Vermont Nut Free Chocolates
Meredith Verona
Stephen Ward
Roberta Wells
Chrissie Wetherbee
Gilbert Wootton
Tim Yerdon
Lori Zych
IN-KIND
Allergic Living
Camille CD Photography
Eleni’s New York
The Mann Report
Materne North America – GoGo squeeZ
OWYN
Personal Attention
Vermont Nut
Free Chocolates
Uncommon
BOARD OF DIRECTORS (2019)
David G. Bunning, Chair
John J. Hannan
Helen Jaffe
Rebecca Lainovic
Adam Miller
Christine Olsen, MD
Elise Purcell
Robert L. Rich
Mary Weiser
Elliot S. Jaffe, Chairman Emeritus

BOARD OF GOVERNORS (2019)
Kim and Alan Hartman, Co-Chairs
Janet Atwater
Denise A. Bunning
Hillary and Ben Carter
David A. Crown, PhD
Talia and Andrew Day
Leigh Feuerstein
Julie and Paul Leff
Kathy and Don Levin
Louise Matthews, MD
Robert Nichols
Joelle Resnick
Cari and Michael J. Sacks
Sara Trachte

26 | FARE 2019 IMPACT REPORT
Please note that the listings for Board of Directors, Board of Governors and Board of National Ambassadors are correct at the time of printing and are subject to change.
JOIN US AND REALIZE A FUTURE WHERE WE REVERSE THE RISE OF THIS DISEASE, AND ULTIMATELY FIND A CURE

Growing recognition of the food allergy epidemic and advances in biomedical research have brought us to an inflection point, a time with great potential for change. FARE is laying the groundwork for breakthroughs in food allergy research, education, advocacy and awareness. Your partnership helps bring us closer to improving the quality of life and the health of individuals with food allergies and providing them hope through new treatments.

www.foodallergy.org